Fatima Khwaja Rehman

Fatima Khwaja Rehman

Auto-generated profile, based on publicly available information

Fatima Khwaja Rehman

University of North Florida

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2020 in International Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
ASArooj Shafiq
Arooj Shafiq
JMJanuary Moore
January Moore
ASAliya Suleman
Aliya Suleman
SFSabeen Faiz
Sabeen Faiz
OFOmar Farooq
Omar Farooq
FRFatima K. Rehman
Fatima K. Rehman
Purpose. Galectin-3 (Gal-3) is a glycan-binding lectin with a debated role in cancer progression due to its various functions and patterns of expression. The current study investigates the relationship between breast cancer prognosis and secreted Gal-3. Methods. Breast cancer patients with first time cancer diagnosis and no prior treatment (n=88) were placed in either adjuvant or neoadjuvant setting based on their treatment modality. Stromal and plasma Gal-3 levels were measured in each patient at the time of diagnosis and then throughout treatment using immunohistochemistry (IHC) and ELISA, respectively. Healthy women (>18 years of age, n=63) were used to establish baseline levels of plasma Gal-3. Patients were followed for 84 months for disease-free survival analysis. Results. Enhanced levels of plasma (adjuvant) and stromal (neoadjuvant) Gal-3 were found to be markers of chemotherapy efficacy. The patients with chemotherapy-induced increase in extracellular Gal-3 had longer disease-free interval and significantly lower rate of recurrence during 84-month follow-up compared to patients with unchanged or decreased secretion. Conclusion. The findings support the use of plasma Gal-3 as a marker for chemotherapy efficacy when no residual tumor is visible through imaging. Furthermore, stromal levels in any remaining tumors postchemotherapy can also be used to predict long-term prognosis in patients.

25 June 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MBMollie A. Brekker
Mollie A. Brekker
TSTala Sartawi
Tala Sartawi
TSTina Sawatzky
Tina Sawatzky
CCCorey P. Causey
Corey P. Causey
FRFatima Khwaja Rehman
Fatima Khwaja Rehman
BKBryan Knuckley
Bryan Knuckley
Protein arginine methyltransferases (PRMTs) are S-adenosylmethionine-dependent enzymes that transfer a methyl group to arginine residues within proteins, most notably histones. The nine characterized PRMT family members are divided into three types depending on the resulting methylated product: asymmetric dimethylarginine (Type I PRMT), symmetric dimethylarginine (Type II PRMT), or monomethylated arginine (Type III PRMT). In some cancers, the resulting product can lead to either increased or decreased transcription of cancer-related genes, suggesting PRMT family members may be valid therapeutic targets. Traditionally, peptide-based compounds have been employed to target this family of enzymes, which has resulted in multiple tool and lead compounds being developed. However, peptide-based therapeutics suffer from poor stability and short half-lives, as proteases can render them useless by hydrolytic degradation. Conversely, peptoids, which are peptide-mimetics composed of N-substituted glycine monomers, are less susceptible to hydrolysis, resulting in improved stability and longer half-lives. Herein, we report the development of a bioavailable, peptoid-based PRMT1 inhibitor that induces cell death in MDA468 and HCT116 cancer cell lines while not exhibiting any significant impact on nontumorigenic HepaRG or normal human mammary epithelial cells. Furthermore, the inhibitor described herein appears to induce both apoptosis and autophagy, suggesting it may be a less toxic cytostatic agent. In conclusion, we propose this peptoid-based inhibitor has significant anticancer and therapeutic potential by reducing cell viability, growth, and size in breast and colon cancer. Further experimentation will help determine the mechanism of action and downstream effects of this compound.

22 January 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SLSok-Hyong Lee
Sok-Hyong Lee
FRFatima Khwaja Rehman
Fatima Khwaja Rehman
KTKari C. Tyler
Kari C. Tyler
BYBing Yu
Bing Yu
ZZZhaobin Zhang
Zhaobin Zhang
EMErwin G Van Meir
Erwin G Van Meir
Purpose: Exploitation of altered glycosylation in cancer is a major goal for the design of new cancer therapy. Here, we designed a novel secreted chimeric signal peptide–Galectin-3 conjugate (sGal-3) and investigated its ability to induce cancer-specific cell death by targeting aberrantly N-glycosylated cell surface receptors on cancer cells. Experimental Design: sGal-3 was genetically engineered from Gal-3 by extending its N-terminus with a noncleavable signal peptide from tissue plasminogen activator. sGal-3 killing ability was tested on normal and tumor cells in vitro and its antitumor activity was evaluated in subcutaneous lung cancer and orthotopic malignant glioma models. The mechanism of killing was investigated through assays detecting sGal-3 interaction with specific glycans on the surface of tumor cells and the elicited downstream proapoptotic signaling. Results: We found sGal-3 preferentially binds to β1 integrin on the surface of tumor cells due to aberrant N-glycosylation resulting from cancer-associated upregulation of several glycosyltransferases. This interaction induces potent cancer-specific death by triggering an oncoglycan-β1/calpain/caspase-9 proapoptotic signaling cascade. sGal-3 could reduce the growth of subcutaneous lung cancers and malignant gliomas in brain, leading to increased animal survival. Conclusions: We demonstrate that sGal-3 kills aberrantly glycosylated tumor cells and antagonizes tumor growth through a novel integrin β1–dependent cell-extrinsic apoptotic pathway. These findings provide proof-of-principle that aberrant N-oncoglycans represent valid cancer targets and support further translation of the chimeric sGal-3 peptide conjugate for cancer therapy.

17 December 2020 in ANNALS OF ABBASI SHAHEED HOSPITAL AND KARACHI MEDICAL & DENTAL COLLEGE
Verified
Journal Article
Open access
PDF file
UHUzma Hameed
Uzma Hameed
SISadia Iqbal
Sadia Iqbal
FRFatima Rehman
Fatima Rehman
AHAisha Hassan
Aisha Hassan
AMAyesha Majeed Memon
Ayesha Majeed Memon
SMSumera Mustafa
Sumera Mustafa
Objective: The objective of the present study was to compare the earlier possible effects of exogenous and endogenous glucocorticoids on the spermatogenesis of albino rats.Methods: This comparative study was conducted at Baqai Medical University in the Department of Anatomy from June till July 2016. Total of 96 adult Sprague rats were used in this study obtained from Agha Khan University; their ages were between 10-12 weeks and their weight ranged between 180-200 gms. Exogenous glucocorticoids were given through intraperitoneal route (i.p. route) at the dose of 1.2 mg/kg/body weight and for endogenous production of cortisol, they were kept in a plastic box daily which was thermostatically maintained at 44º C for 1 hour. They were divided into three main groups and the main group was further categorized into subgroups according to their number of days. The three main groups were; A (control), B (exogenous glucocorticoid), and C (endogenous glucocorticoid). They were sacrificed at the end of the experiment, testes were removed and the effects of exogenous and endogenous glucocorticoids on the spermatogenesis were observed under the light microscope in H&E and PAS stained sections.Results: Spermatogenesis was assessed by Johnsons scoring which ranges from 10 to 1. In the control group, complete spermatogenesis was observed with a Johnson's score of 10 while in group B and C scores were between 10-2 and 10-3, respectively. Conclusion: From the present study, we conclude that exogenous glucocorticoids cause earlier damage and effects all stages of spermatogenesis with decreased production of quality sperms. This animal study will help to decrease the infertility rate due to excessive and unnecessary use of glucocorticoids especially in the early years of life and by taking preventive measures when exposed to high temperatures.

16 July 2023 in Journal of Bahria University Medical & Dental College
Verified
Journal Article
Open access
PDF file
SQSadia Abdul Qayyum
Sadia Abdul Qayyum
HYHina Yousuf
Hina Yousuf
SASyed Mukkaram Ali
Syed Mukkaram Ali
LFLubna Faisal
Lubna Faisal
FRFatima Rehman
Fatima Rehman
Objective: To determine the frequency and factors associated with unintentional trauma and its management in children under 14 years of age. Study Design and Setting: This study is retrospective, descriptive and was conducted at the Pediatric Surgery Department and Emergency Room at Liaquat National Hospital and Medical College, Karachi. Methodology: Total duration of the study was from 1st January 2020 to 31st December 2020 and all the unintentional trauma cases in children below 14 years of age were included. Details of history, examination, and any procedure done were recorded through a predesigned proforma in regard to their age, gender, day of presentation and, factors related to trauma like the anatomical site, place, mode and type of injury along with their treatment outcomes. Descriptive statistics were run using SPSS version 26. Results: Out of 103 children, (66%) were males in the age group of 2-4 years. The surge of injuries was on weekdays (71.8%). Domestic injuries were 68.9% which is significantly higher. The most affected region was the head/ neck (28.2%) with lacerations (40.0%) and bruises (90.0%). Amongst the management outcomes, the invasive procedures were frequent (48.5 %) for laceration (48.0%). Conclusion: Amongst the (6.4%) of unintentional trauma cases, the majority of these injuries were blunt trauma in children under four years of age on the head/ neck region. We conclude that the majority of these pediatric injuries were moderate in nature and required invasive treatment strategies but these injuries are preventable.

31 March 2023
Verified
Other
Open access
SLSok-Hyong Lee
Sok-Hyong Lee
FRFatima Khwaja Rehman
Fatima Khwaja Rehman
KTKari C. Tyler
Kari C. Tyler
BYBing Yu
Bing Yu
ZZZhaobin Zhang
Zhaobin Zhang
EMErwin G Van Meir
Erwin G Van Meir